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national pharmacy (Apoteket AB). Costs were calculated from
a societal perspective by multiplying quantities of resources
used with unit costs (presented in Euros 2007). RESULTS: In
Sweden, about 326,100 patients over 54 years suffer from
acute insomnia (DSM-IV 307.42), a prevalence of about 12%
in this age group. The associated costs exceed €151 million per
year. About 44% are direct costs (outpatient care €40.4 m,
drugs €22.5 m, diagnostic examinations €0.48 m, specialist
visits €0.47 m and inpatient care €0.22 m) and 56% indirect
costs (presenteeism €78.5 m, absenteeism €6.6 m and occupa-
tional and domestic accidents related to daytime dysfunction
caused by poor sleep and current treatment €0.91 m and
€0.57 m, respectively). Other relevant cost items that were not
incorporated in this estimate, due to the high degree of uncer-
tainty, include: cognitive behavioural treatment, productivity
losses due to early retirement, medical costs due to co-
morbidities aggravated by insomnia, side-effects of current
treatment (incl. increased risk of trafﬁc accidents, tolerance,
dependence and withdrawal symptoms), and quality of life
losses. CONCLUSIONS: Our results conﬁrm that insomnia
presents a substantial clinical and economic burden. The
annual cost per patient (€463) is consistent with estimates for
e.g. Germany, France and the US. As a large share of the costs
fall outside the health care system, a societal perspective is
important when evaluating treatments of insomnia.
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OBJECTIVES: To generate national estimates of the inpatient
economic burden of key medical conditions among Asian-
American and Paciﬁc Islander (AAPI) females hospitalized in the
United States in 2005. Conditions analyzed were based upon
research conducted by the US Department of Health and Human
Services, Ofﬁce of Women’s Health, which identiﬁed conditions
of particular concern for this underserved population.
METHODS: Data from the 2005 HCUP Nationwide Inpatient
Sample (NIS) database were analyzed for 438,577 hospital stays
(unweighted = 91,092) for AAPI females. Among these, we iden-
tiﬁed stays in which the primary or second diagnosis, using
relevant ICD-9-CM diagnosis codes, was for tuberculosis (TB),
Hepatitis B (HBV), osteoporosis, cervical cancer (CC), and breast
cancer (BC). Using sampling weights provided with the NIS
dataset, national estimates of mean per-discharge length of stay
(LOS) and total costs, and aggregate (i.e., summed across all
discharges) total days and costs were estimated for each condi-
tion. RESULTS: Among hospitalizations for AAPI women in
2005, we found 485 hospitalizations for TB (with relevant
primary or second diagnosis only), 1237 for HBV, 672 for
osteoporosis, 490 for CC, and 1594 for BC. For each condition,
the mean per-discharge LOS and aggregate total days were 12.3
and 5611; 4.7 and 5804; 3.5 and 2325; 4.7 and 2316; and 2.7
and 4379 days, respectively. Finally, for each condition, the mean
per-discharge and aggregate total costs were $20,563 and
$9,099,718, $10,230 and $11,408,636, $8,284 and $5,269,951,
$10,174 and $4,472,145, and $8,040 and $11,655,081, respec-
tively. CONCLUSIONS: In this study we examined the inpatient
economic burden of illnesses that are of concern for AAPI
women in the US. The total cost incurred for just these 5 condi-
tions (4,478 discharges) was in excess of $40,000,000. Policy
and other decision makers should be aware of the burden of these
conditions as strategies to address these illnesses among this
minority population are developed.
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OBJECTIVES: To assess health care costs associated with a
diagnosis of preeclampsia or hypertension during pregnancy by
describing 5-month antepartum and delivery, and 3-month post-
partum health care costs. METHODS: Pregnancy episodes
(1999–2005) for female claimants ages 15–55 who met continu-
ous enrollment criteria were constructed using a U.S. employer-
based insurance claims database. Episodes were stratiﬁed based
on a diagnosis of preeclampsia (ICD-9 642.4–642.7; N = 2,435),
hypertension during pregnancy (ICD-9 642.0, 642.1, 642.3,
642.9; N = 2,419), or absence of either of these diagnoses
(N = 39,597). Pregnancy-related maternal (5-month antepartum
and delivery, and 3-month postpartum) and neonatal (3-month
postpartum) health care costs were compared using nonparamet-
ric Wilcoxon rank-sum tests, with mean values reported here.
RESULTS: Antepartum and delivery costs were highest for the
preeclampsia group ($13,491), followed by the hypertension
($8,899) and comparison ($8,075) groups (between-group dif-
ferences p < 0.001). Inpatient costs in the preeclampsia group
were 58% ($11,031 vs. $6,961; p < 0.001) and 63% ($11,031
vs. $6,781; p < 0.001) greater than in the hypertension and com-
parison groups, respectively. Maternal postpartum medical costs
in the preeclampsia, hypertension, and comparison groups were
$1623, $1028, and $741, respectively (between-group differ-
ences p < 0.001). Neonatal costs in the preeclampsia group were
much higher than those in the hypertension and comparison
groups ($7035 vs. $2784; p < 0.001 and $7035 vs. $2484;
p < 0.001). More than 60% of all neonatal costs in the preec-
lampsia group were associated with neonatal or pediatric inten-
sive care unit (NICU/PICU) services, compared to less than 40%
in both the hypertension and comparison groups. Total maternal
and neonatal postpartum costs were $8658, $3812, and $3226,
respectively (between-group differences p < 0.001). CONCLU-
SIONS: Pregnancies with a preeclampsia diagnosis are associated
with signiﬁcantly higher maternal antepartum and delivery costs,
and all postpartum costs. Neonatal costs are also signiﬁcantly
higher, largely due to NICU/PICU care of babies born to mothers
with a diagnosis of preeclamspia.
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OBJECTIVES: To evaluate, in a real-life clinical setting, the
utilisation, cost and outcomes of assisted reproduction treatment
(ART) with rFSH and assess whether the economic burden is
consistent with that established by the UK National Institute for
Health and Clinical Excellence (NICE). METHODS: Study
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